Pruritus Relief thru Itch-Scratch Modulation (“PRISM”) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks New Haven, CT, September 27, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER […]
New Haven, CT, March 21, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development company focused on developing Nalbuphine® ER for chronic pruritus (itch), today announced that Jennifer Good, President and Chief Executive Officer, will present at Needham & […]
Highly experienced clinical drug developer to oversee R&D functions and Company’s Phase 3 development program New Haven, CT, October 12, 2017 – Trevi Therapeutics, Inc. (“Trevi” or the “Company”), a late-stage clinical development company focused on developing Nalbuphine® ER for […]
Company continuing the development of Nalbuphine® ER in chronic pruritus conditions New Haven, CT, July 20, 2017 – Trevi Therapeutics, Inc. (“Trevi” or the “Company”), announced today that the Company has completed a Series C financing of $50.5 million led […]